A new drug for pancreatic cancer, one of the deadliest cancers, saw patients live almost double the time compared to those treated with chemotherapy in a clinical trial.

Add Yahoo as a preferred source to see more of our stories on Google. A new pancreatic cancer drug being tested by doctors in Phoenix is showing promise, potentially doubling survival rates for ...

The drug daraxonrasib could be a potential new treatment to double the survival of advanced pancreatic cancer patients, a groundbreaking new clinical trial suggests. Pancreatic cancer patients often ...

The Macomb County (Michigan) Prosecutor's Office has charged a man with receiving and concealing stolen property after a missing dog was returned to its family.

In a press release Monday, Revolution Medicines shared the findings of its Phase 3 clinical trial, which evaluated the drug Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma ...

Adding elraglusib to gemcitabine/nab-paclitaxel met the primary endpoint, improving median overall survival to 10.1 months versus 7.2 months and reducing mortality ...

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may ...

Dr. Shikha Jain discusses a promising new pancreatic cancer treatment nearing approval, how soon patients could access it, and the major advances in care over the past decade.

Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in previously treated metastatic PDAC. Progression-free survival and disease control ...

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.

In a family of killer diseases, pancreatic cancer has long been one of the scariest. It could grow undetected for years, and ...